GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
GRI Bio, a biotechnology company listed on NASDAQ under the ticker GRI, will present at Alliance Global Partner’s 2024 Healthcare Company Showcase. The event is scheduled for May 21, 2024, at 2:40 PM ET. The company specializes in developing Natural Killer T (NKT) cell modulators to treat inflammatory, fibrotic, and autoimmune diseases. Marc Hertz, PhD, CEO of GRI Bio, will participate in a live webcast fireside chat. This event can be accessed through the Investors section on GRI Bio's website.
- Participation in a high-profile event can increase GRI Bio's visibility in the healthcare investment community.
- Showcasing innovative NKT cell modulators may attract potential investors and partners.
- The live webcast provides transparency and accessibility for shareholders and potential investors.
- The announcement lacks concrete financial or clinical data updates, which might be seen as a missed opportunity for investors seeking substantial news.
- No new product developments or milestones were disclosed, which could be perceived as a lack of progress.
Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ET
LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 2:40 PM ET.
A live webcast of the event will be available on the Events page of the Investors section of the Company’s website (www.gribio.com).
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. iNKT cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
FAQ
When will GRI Bio present at the Alliance Global Partner’s 2024 Healthcare Company Showcase?
What is the stock symbol for GRI Bio?
Where can I watch the live webcast of GRI Bio’s presentation?
What is the focus of GRI Bio’s biotechnology pipeline?
